Award recordCONTRACT

MYLAN PHARMACEUTICALS INC

PIID 36E79723D0015· VA Staff Offices· NAC PHARMACEUTICALS (36E797)· 6505 · DRUGS AND BIOLOGICALS· FY2023· $0 net obligations· UEI NDN1MYB8DKK5· WV

Description

2026 SUBCONTRACTING PLAN EFFECTIVE JANUARY 1, 2026 THROUGH DECEMBER 31, 2026 FOR CLOZAPINE TABLETS WITH MYLAN PHARMACEUTICALS.

Base award description: NEW AWARD FOR CLOZAPINE TABLETS WITH MYLAN. ORDERING PERIOD IS MARCH 4, 2023 TO MARCH 3, 2024 WITH FOUR ONE-YEAR OPTIONS

First action · last action
2023-02-02 · 2025-12-31
Transactions
9
First transaction's obligation
$0
Base + all options value (sum of deltas)
$8,346,791
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
2
SDVOSB flag on record
No
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING

Modification chain · 9 transactions

Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.

$1$0Base award · 2023-02-02 · this action $0 · running total $0Modification P00001 · 2023-04-14 · this action $0 · running total $0Modification P00002 · 2023-11-16 · this action $0 · running total $0Modification P00003 · 2024-01-29 · this action $0 · running total $0Modification P00004 · 2024-02-15 · this action $0 · running total $0Modification P00005 · 2024-12-18 · this action $0 · running total $0Modification P00006 · 2025-01-24 · this action $0 · running total $0Modification P00007 · 2025-12-18 · this action $0 · running total $0Modification P00008 · 2025-12-31 · this action $0 · running total $0
  • Base2023-02-02+$0= $0
  • Mod P000012023-04-14+$0= $0
  • Mod P000022023-11-16+$0= $0
  • Mod P000032024-01-29+$0= $0
  • Mod P000042024-02-15+$0= $0
  • Mod P000052024-12-18+$0= $0
  • Mod P000062025-01-24+$0= $0
  • Mod P000072025-12-18+$0= $0
  • Mod P000082025-12-31+$0= $0
TransactionAction dateThis action (delta)Running totalDescription on this transaction
Base2023-02-02+$0$0NEW AWARD FOR CLOZAPINE TABLETS WITH MYLAN. ORDERING PERIOD IS MARCH 4, 2023 TO MARCH 3, 2024 WITH FOUR ONE-YE…
Mod P00001· OTHER ADMINISTRATIVE ACTION2023-04-14+$0$0INCORPORATING DSCSA FOR CLOZAPINE TABLETS WITH MYLAN PHARMACEUTICALS, INC. EFFECTIVE 5/15/2023.
Mod P00002· ADD SUBCONTRACTING PLAN2023-11-16+$0$0INCORPORATING 2024 SUBCONTRACTING PLAN FOR CLOZAPINE TABLETS WITH MYLAN PHARMACEUTICALS, INC. EFFECTIVE 1/1/20…
Mod P00003· EXERCISE AN OPTION2024-01-29+$0$0EXERCISE OPTION YEAR 1 EFFECTIVE MARCH 4, 2024 THROUGH MARCH 3, 2025 FOR CLOZAPINE TABLETS WITH MYLAN PHARMACE…
Mod P00004· SUPPLEMENTAL AGREEMENT FOR WORK WITHIN SCOPE2024-02-15+$0$0CHANGE IN COST RECOVERY FEE SUBMITTAL AND SALES REPORTING PROCEDURES
Mod P00005· ADD SUBCONTRACTING PLAN2024-12-18+$0$02025 SUBCONTRACTING PLAN
Mod P00006· EXERCISE AN OPTION2025-01-24+$0$0EXERCISE OPTION YEAR 2 EFFECTIVE MARCH 4, 2025 THROUGH MARCH 3, 2026 FOR CLOZAPINE TABLETS WITH MYLAN PHARMACE…
Mod P00007· EXERCISE AN OPTION2025-12-18+$0$0EXERCISE OPTION YEAR 3 EFFECTIVE MARCH 4, 2026 THROUGH MARCH 3, 2027 FOR CLOZAPINE TABLETS WITH MYLAN PHARMACE…
Mod P00008· ADD SUBCONTRACTING PLAN2025-12-31+$0$02026 SUBCONTRACTING PLAN EFFECTIVE JANUARY 1, 2026 THROUGH DECEMBER 31, 2026 FOR CLOZAPINE TABLETS WITH MYLAN…

Related awards · 11

Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.

Other VA awards to the same recipient (UEI NDN1MYB8DKK5)

AwardOffice · PSC / listingNet obligationsFY
36E79726D0033NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2026
36E79725D0054NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2025
36F79723D0025NAC FEDERAL SUPPLY SCHEDULE (36F797) · 6505 · DRUGS AND BIOLOGICALS$0FY2023
36E79722D0014NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2022
36E79721N0050NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$0FY2021
36E79721N0043NAC PHARMACEUTICALS (36E797) · 6505 · DRUGS AND BIOLOGICALS$116,444FY2021

Other recipients under 6505 from NAC PHARMACEUTICALS (36E797) (most recent first)

AwardRecipientOfficeNet obligationsFY
36E79726A0025CHIESI USA INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0024NEUROTECH PHARMACEUTICALS, INCNAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0023TAKEDA PHARMACEUTICALS AMERICA, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726D0041GOLDEN STATE MEDICAL SUPPLY, INC.NAC PHARMACEUTICALS (36E797)$0FY2026
36E79726A0022AURINIA PHARMA US INCNAC PHARMACEUTICALS (36E797)$0FY2026

Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_IDV_36E79723D0015_3600 · retrieved 2026-09-26.